Cardiothoracic Division, The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK.
Heart. 2012 Oct;98(19):1407-11. doi: 10.1136/heartjnl-2012-302459. Epub 2012 Jul 11.
Many countries have embarked on national strategies to translate evidence from trials of reperfusion therapy for ST-elevation myocardial infarction (STEMI) into clinical practice. Primary angioplasty has become the dominant mode of reperfusion, but the best outcomes depend on appropriate service re-configurations to ensure rapid, effective and comprehensive treatment. Although there are many differences in the treatment of STEMI and non-STEMI acute coronary syndromes (ACS), there are many parallels. Many of the changes in the system of care for STEMI patients could now be applied to the non-STEMI ACS population, providing faster and more efficient care and promising to deliver better outcomes. This article highlights additional changes to healthcare services that should be considered.
许多国家已经开始制定国家战略,将 ST 段抬高型心肌梗死(STEMI)再灌注治疗试验中的证据转化为临床实践。直接经皮冠状动脉介入治疗已成为再灌注的主要方式,但最佳疗效取决于适当的服务重构,以确保快速、有效和全面的治疗。尽管 STEMI 和非 ST 段抬高型急性冠状动脉综合征(ACS)的治疗存在许多差异,但也有许多相似之处。现在,STEMI 患者的医疗服务系统中的许多变化都可以应用于非 ST 段抬高型 ACS 人群,提供更快、更有效的护理,并有望带来更好的结果。本文强调了应该考虑对医疗服务进行的其他改变。